Tislelizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB14922 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 31 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | mixed-type autoimmune hemolytic anemia | KG + DL |
| 2 | idiopathic aplastic anemia | KG + DL |
| 3 | dermatitis | KG + DL |
| 4 | paroxysmal nocturnal hemoglobinuria | KG + DL |
| 5 | drug-induced autoimmune hemolytic anemia | KG + DL |
| 6 | proteinuria | KG + DL |
| 7 | acne keloid | KG + DL |
| 8 | neonatal autoimmune hemolytic anemia | KG + DL |
| 9 | primary CD59 deficiency | KG + DL |
| 10 | amyopathic dermatomyositis | KG + DL |
| 11 | neonatal dermatomyositis | KG + DL |
| 12 | cold agglutinin disease | KG + DL |
| 13 | hydroa vacciniforme, familial | KG + DL |
| 14 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 15 | acrodermatitis chronica atrophicans | KG + DL |
| 16 | hepatic veno-occlusive disease-immunodeficiency syndrome | KG + DL |
| 17 | pancytopenia due to IKZF1 mutations | KG + DL |
| 18 | chromhidrosis | KG + DL |
| 19 | adult idiopathic neutropenia | KG + DL |
| 20 | congenital neutropenia-myelofibrosis-nephromegaly syndrome | KG + DL |
| 21 | Dowling-Degos disease | KG + DL |
| 22 | autosomal recessive severe congenital neutropenia due to JAGN1 deficiency | KG + DL |
| 23 | psoriasis | KG + DL |
| 24 | X-linked severe congenital neutropenia | KG + DL |
| 25 | autosomal recessive severe congenital neutropenia due to CXCR2 deficiency | KG + DL |
| 26 | cyclic hematopoiesis | KG + DL |
| 27 | autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis | KG + DL |
| 28 | thrombocytopenia due to immune destruction | KG + DL |
| 29 | combined immunodeficiency due to CRAC channel dysfunction | KG + DL |
| 30 | hidradenitis | KG + DL |
| 31 | facial dysmorphism-immunodeficiency-livedo-short stature syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.